<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01564368</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000729174</org_study_id>
    <secondary_id>ACRIN-6698</secondary_id>
    <secondary_id>U01CA080098</secondary_id>
    <secondary_id>U01CA079778</secondary_id>
    <nct_id>NCT01564368</nct_id>
  </id_info>
  <brief_title>DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy</brief_title>
  <acronym>ACRIN6698</acronym>
  <official_title>Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And MoLecular Analysis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American College of Radiology Imaging Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>American College of Radiology Imaging Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imaging procedures, such as diffusion-weighted magnetic resonance imaging (DWI)
      and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), may help in evaluating
      how well patients with breast cancer respond to treatment.

      PURPOSE: This research trial studies DWI and DCE-MRI in assessing treatment response in
      patients with breast cancer undergoing neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if the change in tumor apparent diffusion coefficient (ADC) value measured
           from each treatment timepoint to baseline is predictive of pathologic complete response
           (pCR).

      Secondary

        -  To determine if the combined measurement of change in tumor ADC value, change in tumor
           volume, and change in peak signal-enhancement ratio (SER) is predictive of pCR.

        -  To investigate the relative effectiveness of the individual measurements, change in
           tumor ADC value, change in tumor volume, and change in peak SER for predicting pCR in
           experimental treatment arms.

        -  To assess the test-retest reproducibility of ADC metrics applied to breast tumors.

      OUTLINE: This is a multicenter study.

      Patients undergo diffusion-weighted magnetic resonance imaging (DWI) at baseline, after week
      3 of neoadjuvant paclitaxel regimen, and prior to and after completion of 4 courses of
      neoadjuvant chemotherapy. Patients then undergo surgery. Patients undergo DWI prior to
      contrast administration for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

      After completion of treatment procedure, patients are followed up for 5 years on the I-SPY 2
      TRIAL.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR)</measure>
    <time_frame>Until surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ADC value as measured by area under the receiver operating characteristic curve from each treatment timepoint to baseline</measure>
    <time_frame>Until surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in ADC value, DCE-MRI tumor volume, and SER</measure>
    <time_frame>Until surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of the individual measurement's changes in ADC value, DCE-MRI tumor volume, and SER</measure>
    <time_frame>Until surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test-retest reproducibility of DW-MRI ADC metric</measure>
    <time_frame>Pre-treatment MRI</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Diffusion Weighted-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion-weighted magnetic resonance imaging</intervention_name>
    <description>diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation</description>
    <arm_group_label>Diffusion Weighted-MRI</arm_group_label>
    <other_name>functional MRI</other_name>
    <other_name>DWI</other_name>
    <other_name>diffusion-weighted MRI</other_name>
    <other_name>DW-MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets I-SPY 2 TRIAL inclusion criteria

               -  High-risk for recurrent disease

        PATIENT CHARACTERISTICS:

          -  Able to tolerate imaging required by protocol

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nola M. Hylton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington/SCCA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT01564368</url>
    <description>National Cancer Institute's Clinical trial database</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2012</study_first_submitted>
  <study_first_submitted_qc>March 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>See ACRIN data sharing Policy https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

